• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Whitehawk Therapeutics Inc.

    5/15/25 6:46:15 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WHWK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Whitehawk Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    00032Q104

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00032Q104


    1Names of Reporting Persons

    OrbiMed Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,166,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,166,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,166,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    00032Q104


    1Names of Reporting Persons

    OrbiMed Genesis GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,166,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,166,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,166,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Whitehawk Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    2 Headquarters Plaza, East Building, 11th Floor Morristown, New Jersey 07960
    Item 2. 
    (a)Name of person filing:

    OrbiMed Advisors LLC OrbiMed Genesis GP LLC
    (b)Address or principal business office or, if none, residence:

    601 Lexington Avenue, 54th Floor New York, NY 10022
    (c)Citizenship:

    Please refer to Item 4 on each cover sheet for each filing person.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    00032Q104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    OrbiMed Advisors LLC: 4,166,000 OrbiMed Genesis GP LLC: 4,166,000
    (b)Percent of class:

    OrbiMed Advisors LLC: 8.9% OrbiMed Genesis GP LLC: 8.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    OrbiMed Advisors LLC: 0 OrbiMed Genesis GP LLC: 0

     (ii) Shared power to vote or to direct the vote:

    OrbiMed Advisors LLC: 4,166,000 OrbiMed Genesis GP LLC: 4,166,000

     (iii) Sole power to dispose or to direct the disposition of:

    OrbiMed Advisors LLC: 0 OrbiMed Genesis GP LLC: 0

     (iv) Shared power to dispose or to direct the disposition of:

    OrbiMed Advisors LLC: 4,166,000 OrbiMed Genesis GP LLC: 4,166,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Reporting Persons hold 8.9% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    OrbiMed Advisors LLC
     
    Signature:/s/ Carl L. Gordon
    Name/Title:Carl L. Gordon / Member
    Date:05/15/2025
     
    OrbiMed Genesis GP LLC
     
    Signature:/s/ Carl L. Gordon
    Name/Title:Carl L. Gordon / Member of OrbiMed Advisors LLC
    Date:05/15/2025
    Get the next $WHWK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WHWK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WHWK
    SEC Filings

    View All

    SEC Form 10-Q filed by Whitehawk Therapeutics Inc.

    10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    8/7/25 4:25:08 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    8/7/25 8:03:57 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Whitehawk Therapeutics Inc.

    8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    6/13/25 4:39:10 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Zhao Baiteng

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/17/25 8:10:46 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Desai Neil

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/17/25 4:37:32 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hirmand Mohammad

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/16/25 4:58:37 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support the biotech's clinical trial

    10/16/25 8:30:00 AM ET
    $TEM
    $WHWK
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

    MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.A live webcast of the fireside chat events can be

    9/2/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

    MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the second quarter ended June 30, 2025, and provided recent corporate progress. "We're pleased with the progress made in Q2 to advance our ADC portfolio and remain on track to file INDs for our first two programs – HWK-007 and HWK-016 – by year-end 2025, with the third program, HWK-206, to follow in mid-2026," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "We believe we are well-positioned to advan

    8/7/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care